Drug Shortage Legislation Gains Support As Coronavirus Threatens US Supplies
Executive Summary
Coronavirus hysteria sweeps up languishing drug shortage legislation; prospects for new reporting and risk management planning requirements improve.
You may also be interested in...
ICH Q9 Revision Delayed By Three Months Due To COVID; Focus Spans Risk Assessments, Shortages
Extension will add training materials with goal of reducing quality defects and recalls. Revision process will also address shortage indicators related to production failures in an attempt to head off drug shortages.
Global Supply Chain Security Meets US Presidential Politics
Joe Biden’s presidential campaign now has a plan to address supply chains and encourage US-based manufacturing of prescription drugs. That affirms the unlikely national prominence of the issue – and reduces the chances of meaningful legislation this year.
COVID-19 Funds Flow To Startup In Bid To Restore US Pharmaceutical Manufacturing
Trump administration infuses Phlow with potentially $800m-plus for fully integrated domestic manufacture of essential medicines for COVID-19 and other crises. Key figures in new approaches to securing drugs and experts on China helped frame the project’s approach.